Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-host Disease

Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures

Abstract

Oral chronic GVHD (cGVHD) is a common, late complication of alloSCT that is associated with significant patient morbidity. The NIH Oral Mucosal Score (NIH OMS) was developed to assess oral cGVHD therapeutic response, but has not been fully validated. This study’s purpose was to conduct a rigorous construct validity and internal consistency analysis of this score and its components (erythema, lichenoid, ulcers, mucoceles) using established measures of oral pain, oral function, oral-related quality-of-life, nutrition and laboratory parameters in 198 patients with cGVHD. The construct validity of the NIH OMS was supported: a moderate correlation was observed between NIH OMS and mouth pain (rho=0.43), while a weaker correlation was observed with low albumin (rho=−0.26). Total NIH OMS, erythema and lichenoid components were associated with malnutrition, oral pain and impaired oral QOL, while ulcers were only associated with oral pain. No associations were found between mucoceles and any indicator evaluated, including salivary function or xerostomia. Kappa determined between scale components was low overall (all 0.35), supporting a conclusion that each component measures a distinct manifestation of oral cGVHD. This study supports the use of the NIH OMS and its components (erythema, lichenoid and ulcerations) to measure clinician-reported severity of oral cGVHD.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.

    Article  CAS  Google Scholar 

  2. Baird K, Pavletic SZ . Chronic graft versus host disease. Curr Opin Hematol 2006; 13: 426–435.

    Article  Google Scholar 

  3. Schubert MM, Correa ME . Oral graft-versus-host disease. Dent Clin North Am 2008; 52: 79–109.

    Article  Google Scholar 

  4. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  Google Scholar 

  5. Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC . Oral graft-versus-host disease. Oral Dis 2008; 14: 396–412.

    Article  CAS  Google Scholar 

  6. Fassil H, Bassim C, Mays J, Edwards D, Baird K, Steinberg S et al. Oral chronic graft-vs-host disease characterization using the NIH scale. J Dent Res 2012; 91: 45S–51S.

    Article  CAS  Google Scholar 

  7. Fall-Dickson JM, Mitchell SA, Marden S, Ramsay ES, Guadagnini JP, Wu TX et al. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 948–956.

    Article  Google Scholar 

  8. Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H et al. Oral chronic graft-versus-host disease report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Invest 2011; 15: 127–139.

    Article  Google Scholar 

  9. Bassim C, Ambatipudi K, Mays J, Edwards D, Swatkoski S, Fassil H et al. Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. J Clin Immunol 2012; 32: 1390–1399.

    Article  CAS  Google Scholar 

  10. Treister N, Duncan C, Cutler C, Lehmann L . How we treat oral chronic graft-versus-host disease. Blood 2012; 120: 3407–3418.

    Article  CAS  Google Scholar 

  11. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252–266.

    Article  Google Scholar 

  12. Elad S, Zadik Y, Zeevi I, Miyazaki A, de Figueiredo MA, Or R . Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence. Transplantation 2010; 90: 1243–1244.

    Article  Google Scholar 

  13. Mitchell SA, Jacobsohn D, Thormann Powers KE, Carpenter PA, Flowers ME, Cowen EW et al. A multicenter pilot evaluation of the national institutes of health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant 2011; 17: 1619–1629.

    Article  Google Scholar 

  14. Treister NS, Stevenson K, Kim H, Woo SB, Soiffer R, Cutler C . Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant 2010; 16: 108–114.

    Article  Google Scholar 

  15. Treister N, Chai X, Kurland B, Pavletic S, Weisdorf D, Pidala J et al. Measurement of oral chronic GVHD: results from the chronic GVHD Consortium. Bone Marrow Transplant 2013; 48: 1123–1128.

    Article  CAS  Google Scholar 

  16. Lee S, Cook EF, Soiffer R, Antin JH . Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 444–452.

    Article  Google Scholar 

  17. Slade G, Spencer A . Development and evaluation of the Oral Health Impact Profile. Community Dent Health 1994; 11: 3–11.

    CAS  Google Scholar 

  18. McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19: 357–368.

    Article  CAS  Google Scholar 

  19. Bauer J, Capra S, Ferguson M . Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr 2002; 56: 779–785.

    Article  CAS  Google Scholar 

  20. Agresti A . Categorical Data Analysis. John Wiley and Sons, Inc.: New York, NY, 1990.

    Google Scholar 

  21. Hollander M, Wolfe D . Nonparametric Statistical Methods, Second Edition. John Wily and Sons, Inc.: New York, 1999.

    Google Scholar 

  22. Mehta C, Patel N . A network algorithm for performing Fisher’s exact test in r x c contingency tables. J Am Stat Assoc 1983; 78: 427–434.

    Google Scholar 

  23. Cohen J . Statistical power analysis for the behavioral sciences. L Erlbaum Associates: Hillsdale, NJ, 1988.

    Google Scholar 

  24. Elad S, Zeevi I, Or R, Resnick IB, Dray L, Shapira MY . Validation of the National Institutes of Health (NIH) scale for oral chronic graft-versus-host disease (cGVHD). Biol Blood Marrow Transplant 2010; 16: 62–69.

    Article  Google Scholar 

  25. Mays J, Fassil H, Edward D, Pavletic S, Bassim C . Oral chronic graft-versus-host disease: Current pathogenesis, therapy, and research. Oral Dis 2012; 19: 327–346.

    Article  Google Scholar 

  26. Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant 2010; 16: 1362–1369.

    Article  Google Scholar 

  27. Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, Ghavamzadeh A, Tohidast-Acrad Z . Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 2007; 39: 431–434.

    Article  CAS  Google Scholar 

  28. Gotoh S, Watanabe Y, Fujibayashi T . Validity of stimulated whole saliva collection as a sialometric evaluation for diagnosing Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 299–302.

    Article  Google Scholar 

  29. Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia 2012; 26: 633–643.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

H Fassil’s research year was made possible through the Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer Inc., and by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institute of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C W Bassim.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bassim, C., Fassil, H., Mays, J. et al. Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures. Bone Marrow Transplant 49, 116–121 (2014). https://doi.org/10.1038/bmt.2013.137

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.137

Keywords

This article is cited by

Search

Quick links